

13281 U.S. PTO  
011304

MORGAN L. FITCH, JR.  
FRANCIS A. EVEN\*  
JULIUS TABIN  
JOHN F. FLANNERY  
ROBERT B. JONES  
JAMES J. SCHUMANN  
JAMES J. HAMILL  
TIMOTHY E. LEVSTIK  
JOSEPH E. SHIPLEY  
KENNETH H. SAMPLES  
PHILIP T. PETTI  
JOSEPH T. NABOR  
STEVEN C. SCHROER  
RICHARD A. KABA\*  
KARL R. FINK  
MARK W. HETZLER  
TIMOTHY P. MALONEY  
JAMES P. KRUEGER  
STEPHEN S. FAVAKEH  
EDWARD W. GRAY, JR.\*  
RICHARD E. WAWRZYNAK  
STEVEN G. PARMELEE  
SHERRI N. BLOUNT\*  
BRUCE R. MANSFIELD  
KENDREW H. COLTON\*  
G. PAUL EDGELL\*  
RICHARD W. SCHUMACHER  
MICHAEL A. SANZO\*

## FITCH, EVEN, TABIN & FLANNERY

ATTORNEYS AND COUNSELLORS AT LAW

*Established in 1859*

SUITE 401L - 1801 K STREET, NW  
WASHINGTON, D.C. 20006-1201

TELEPHONE (202) 419-7000

FACSIMILE (202) 419-7007

### ILLINOIS OFFICE

SUITE 1600 - 120 SOUTH LASALLE STREET, CHICAGO, ILLINOIS 60603-3406

TELEPHONE (312) 577-7000

### CALIFORNIA OFFICE

SUITE 250 - 9276 SCRANTON ROAD, SAN DIEGO, CA 92121-7707

TELEPHONE (858) 552-1311

### COLORADO OFFICE

SUITE 213 - 1942 BROADWAY, BOULDER, COLORADO 80302

TELEPHONE (303) 402-6966

CHRISTOPHER E. GEORGE\*  
SCOTT J. MENGHINI  
EDWARD E. CLAIR  
SANDRA V. SCAVO  
JON A. BIRMINGHAM  
RUDY KRATZ  
RAMON R. HOCH\*  
JOHN E. LYHUS  
STEVEN M. FREELAND  
DONNA E. BECKER  
SEAN R. O'DOWD  
MICHAEL G. VRANICAR  
BRIAN S. CLISE  
MARTIN R. BADER  
DEREK L. PRESTIN  
MARK A. BORSOS  
DAVID R. JAGLOWSKI  
W. BRIAN EDGE\*

### PATENT AGENTS

ERIC J. WHITESELL  
JONATHAN H. BACKENSTOSE  
LILIA I. SAFONOV

### OF COUNSEL

THOMAS F. LEBENS  
GEORGE W. SPELLMIRE, JR.  
LISA M. SOMMER

17497 U.S. PTO  
10/755854

011304

January 13, 2004

Commissioner of Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, **MS Patent Application**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Re: New U.S. Patent Application  
(Claiming Priority to Provisional Appl. No. 60/440,029)  
Appl. No.: to be assigned  
Filed: herewith  
Title: **Eosinophil-Derived Neurotoxin as a  
Marker for Ovarian Cancer**  
Inventor(s): Ye, *et al.*  
Atty. Dkt.: 7570/80962

Dear Sir:

The following documents are being forwarded for appropriate action by the U.S. Patent and Trademark Office:

1. U.S. Patent Application entitled:

### **EOSINOPHIL-DERIVED NEUROTOXIN AS A MARKER FOR OVARIAN CANCER**

and naming as inventor(s): Bin Ye  
Daniel W. Cramer  
Samuel C. Mok

\*ADMITTED TO D.C. BAR; D.C. PRACTICE OF  
ALL OTHERS LIMITED TO FEDERAL COURTS  
AND AGENCIES

the application comprising:

- 19 pages of Specification (numbered as pages 1-19),
  - 3 pages of Claims (numbered as pages 20-22),
  - a one-page Abstract (numbered as page 23),
  - 3 sheets of Formal Drawings (labeled as Fig. 1 - Fig. 6), and
  - 2 pages of Sequence Listing (numbered separately as pages 1-2);
2. Declaration (37 C.F.R. § 1.63) and Power of Attorney of inventors Bin Ye, Daniel W. Cramer and Samuel C. Mok, unexecuted (4 pages);
  3. Assignment to The Brigham and Women's Hospital, Inc. by inventors Bin Ye, Daniel W. Cramer and Samuel C. Mok, unexecuted (2 pages);
  4. A 3.5 inch computer diskette containing a computer readable form of the Sequence Listing;
  5. General Authorization for Petition for Extension of Time Under 37 C.F.R. § 1.136(a)(3);
  6. General Authorization to Charge Deposit Account; and
  7. Two (2) return postcards.

This application claims the benefit of U.S. provisional application no. 60/440,029, filed January 15, 2003, which is incorporated in its entirety herein by reference.

In accordance with 37 C.F.R. § 1.821(f), Applicants' undersigned attorney hereby states that the information recorded in the enclosed computer readable copy of the Sequence Listing and the paper copy of the Sequence Listing are the same.

A separate written request under 37 C.F.R. § 1.136(a)(3), which is a general authorization to treat any concurrent or future reply requiring a petition for an extension of time under 37 C.F.R. § 1.136(a) for its timely submission as incorporating a petition for an extension of time for the appropriate length of time, is enclosed.



13281 U.S. PTO

Commissioner of Patents  
January 13, 2004  
Page 3

### Fee Calculation

Applicants calculate the filing fee is as follows (**Small Entity Status is claimed**):

	Total		No. Extra	Rate	Fee
Basic Filing Fee					385.00
Total Claims Fee	42	20=	22	\$ 9.00	198.00
Independent Claims Fee	3	3 =	0	\$ 43.00	0.00
Multiple Dependent Claims Fee				\$ 145.00	145.00
<b>TOTAL FEES DUE</b>					<b>\$ 728.00</b>

The application is being filed under 37 C.F.R. § 1.53 without the declaration and without the filing fee.

It is respectfully requested that the enclosed postcards be stamped with the date the enclosed documents are received by the PTO and the serial number and that they be returned as soon as possible.

Very truly yours,

FITCH, EVEN, TABIN & FLANNERY

Michael A. Sanzo  
Reg. No. 36,912  
Attorney for Applicants

MAS:ct  
Enclosures



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of:

Ye, *et al.*

Appl. No.: to be assigned

Filed: herewith

For: **Eosinophil-Derived Neurotoxin as a  
Marker for Ovarian Cancer**

Art Unit: to be assigned

Examiner: to be assigned

Atty. Dkt.: 7570/80962

**General Authorization for Petition for  
Extension of Time Under 37 C.F.R. § 1.136(a)(3)**

Commissioner of Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, **MS Patent Application**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir:

Applicants hereby request under 37 C.F.R. § 1.136(a)(3) by this general authorization that any concurrent or future reply submitted by Applicants to the United States Patent and Trademark Office for the above-identified patent application requiring a petition for an extension of time under § 1.136(a) for its timely submission be treated as incorporating therein a petition for an extension of time for the appropriate length of time.


If Applicants do not timely pay for any extension fee(s) pursuant to 37 C.F.R. § 1.136(a) which may become due for this application under 37 C.F.R. § 1.17 by check, the Director is hereby authorized to charge such fee(s), and any additional fees which may be required in this application under 37 C.F.R. §§ 1.16-1.17 during its entire pendency, or credit any overpayment, to Deposit Account No. 06-1135 under Order No. 7570/80962.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By Michael A. Sanzo  
Michael A. Sanzo  
Reg. No. 36,912  
Attorney for Applicants

Date January 13, 2003  
1801 K Street, N.W., Suite 401L  
Washington, DC 20006-1201  
Phone: (202) 419-7013



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of:

Ye, *et al.*

Appl. No.: to be assigned

Filed: herewith

For: **Eosinophil-Derived Neurotoxin as a  
Marker for Ovarian Cancer**

Art Unit: to be assigned

Examiner: to be assigned

Atty. Dkt.: 7570/80962

**General Authorization to Charge Deposit Account**

Commissioner of Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, **MS Patent Application**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir:

The Commissioner is hereby authorized to charge any additional fees which may be required in this application under 37 C.F.R. §§1.16-1.17 during its entire pendency, or credit any overpayment, to Deposit Account No. 06-1135 under Order No. 7570/80962.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By Michael A. Sanzo  
Michael A. Sanzo  
Reg. No. 36,912  
Attorney for Applicants

Date January 13, 2003  
1801 K Street, N.W., Suite 401L  
Washington, DC 20006-1201  
Phone: (202) 419-7013